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A recent Nature Medicine study by Eppert et al. (2011) describes analyses of functionally defined leukemia
stem cell populations that provide new insights on the biology of human tumor populations and the potential
use of stem cell-associated gene signatures for prognosis.With the advent of comprehensive gene
expression analysis platforms, transcrip-
tional profiles of almost any cell type can
be readily obtained. This approach has
a variety of applications, including that of
a prognostic tool for human disease. In
the cancer field, numerous studies have
employed genome-wide transcriptional
signatures to determine the biological
state of a tumor and to make predictions
on the efficacy of conventional therapy.
Retrospective analyses have shown that
various signatures can identify good-
and poor-prognosis patients (Liu et al.,
2007), and in conjunction with more con-
ventional methods (e.g., cytogenetics,
mutational analyses, etc.) may allow opti-
mization of therapy.
One challenge in applying transcrip-
tional analyses to cancer studies is that
most tumors, like the tissues from which
they are derived, are composed of hetero-
geneous cell populations (Rosen and
Jordan, 2009). Such cellular diversity is
of course frequently accompanied by
distinct expression profiles. Thus, a limita-
tion of bulk tissue profiling is that it may
not be representative of the expression
profile of a specific subpopulation. In
particular, if tumor-initiating cells, or so-
called ‘‘cancer stem cells’’ (CSCs) are
present as a relatively minor subpopula-
tion, their transcriptional status is likely
to be obscured by the presence of bulk
tumor cells with differing expression
profiles.
An obvious means to address this issue
is to enrich for stem cell populations using
standard methods, which typically rely on
cell surface antigens and antibody-based
cell sorting. In normal tissues this strategy
has been very effective because of the
presence of a consistently maintained
hierarchical organization and conserved
expression of specific stem cell antigens,
features that permit enrichment of stemcells to a high degree. Thus, genome-
wide expression studies for normal stem
cell populations have facilitated the iden-
tification of the many genes involved in
the regulation of stem cell function or the
determinants of ‘‘stemness’’ (Zon, 2008).
In leukemia, this approach has proven
to be much more challenging than origi-
nally envisioned due to the interpatient
and intrapatient variability of leukemia
stem cell (LSC) phenotypes. Indeed, it
seems that cell surface antigens ex-
pressed on LSCs can vary from patient
to patient, and may change within an
individual patient during the course of
disease pathogenesis (Taussig et al.,
2010). Recent data relying on cell surface
antigen expression indicates that in
some cases LSC functional activity may
be present in more than one popula-
tion (Sarry et al., 2011). Despite these
limitations, prior studies that performed
genome-wide expression profiling of
LSCs have led to the identification of
several pathways involved in regulating
LSC function (Krivtsov et al., 2006; Majeti
et al., 2009). Many of these genes and
pathways have been shown to be impor-
tant to malignant stem cell activity using
gain- or loss-of-function analyses. In
addition, the results of such studies have
been shown to provide prognostic infor-
mation for the segregation of patients
into high-risk and low-risk groups when
applied retrospectively to established
microarray data sets (Gentles et al., 2010).
In an intriguing new study by Eppert
et al. (2011) in Nature Medicine, the
authors report the results of a genome-
wide expression analysis of enriched
LSC populations derived from acute
myeloid leukemia (AML) patients. The
major technical feature that sets this
study apart from previous reports is the
exclusive use of functionally defined LSC
populations. The authors employed anti-Cell Stem Cell 9, Sbodies for CD34 and CD38, the most
common antigens used in the analysis
of primitive human hematopoietic stem
and progenitor populations, and isolated
the four distinct subpopulations that can
be obtained with these two markers
(CD34+/CD38+, CD34+/CD38, CD34/
CD38+, and CD34/CD38) from 16
primary AML patient specimens. Each
sorted fraction was then independently
evaluated for stem cell potential by trans-
plantation into immune-deficient mice.
The data shows that in over 90% of the
patient samples tested, LSCs are present
in the CD34+/CD38 compartment. In
nearly 60% of samples, the CD34+/
CD38+ population also possessed func-
tional LSCs, while in less than one-fourth
of the samples, LSC activity was identified
in the remaining CD34/CD38+ and
CD34/CD38 populations. Limiting-
dilution studies also examined the fre-
quency of LSCs in each fraction and
found that in most samples the CD34+/
CD38 cells were the most highly en-
riched for LSCs, with frequencies on the
order of 1/1,000 to 1/100,000.
Using 25 sorted fractions containing
functionally validated LSCs versus 26
fractions with no detectable LSCs, the
authors then perform comprehensive
gene expression studies and identify
42 genes preferentially expressed in
tumor-forming cell-containing popula-
tions, termed the LSC-R signature.
Notably, 18 genes from the LSC-R signa-
ture are implicated in regulation of normal
or malignant stem cells (e.g., MEIS1,
ERG, HLF, EVI1, etc.), indicating a clear
association with stem cell function. Using
a similar strategy, they also identify a gene
set consisting of 121 genes that represent
the profile of normal hematopoietic stem
cells, the HSC-R signature. By comparing
the LSC-R and HSC-R signatures, they
found that the HSC-R gene signatureeptember 2, 2011 ª2011 Elsevier Inc. 185
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conversely, the LSC-R signature was en-
riched in the HSC-R signature. They
conclude that the extensive overlap of
these two signatures highlights a stem-
ness profile shared between both popula-
tions despite their normal and malignant
origins. Finally, by comparing the HSC-R
and LSC-R signatures, they also identified
a set of 134 genes preferentially upregu-
lated in LSCs versus HSCs that may
represent targets for therapy.
Next, to evaluate the prognostic utility
of their gene expression profiles, the
authors examined data from cohorts of
AML patients treated according to the
protocols of the Dutch–Belgian Hema-
tology–Oncology Cooperative group, for
which gene expression and linked clinical
outcome data is available. They found
that expression of either the LSC-R or
HSC-R profiles correlated with poor prog-
nosis and worse clinical outcomes.
Subsequent studies investigated AML
patients that presented with normal cyto-
genetics. In this cohort, the LSC-R sig-
nature was examined using a multivariate
analysis with standard risk factors (Flt3,
NPM1, CEBPa mutation status, age, and
white blood cell counts). Again, the
LSC-R profile was independently able to
identify subsets of patients at increased
risk of relapse and poor overall survival.
Predictive and prognostic biomarkers
offer the potential to personalize cancer
medicine, and the growth in this research
area in the last decade has been tremen-
dous. In AML, the use of molecular
features of the disease to assign treat-
ment is part of everyday practice. As
novel mutations and recurrent chromo-
somal abnormalities are identified, each
undergoes rigorous evaluation and vali-
dation using multiple tissue and data186 Cell Stem Cell 9, September 2, 2011 ª20repositories. Thus, a next step for the
signatures defined by Eppert et al. will
be independent validation by other
groups, followed by clinical trials in
which treatment is assigned based the
individual patient’s stemness signature
so as to determine the clinical impact of
this approach. As yet, gene profiling in
AML has not reached the status it has
for other malignancies, such as breast
cancer and colorectal cancer. The LSC
signature described by Eppert et al. will
hopefully provide a clinical tool that
will allow the patients at highest risk to
be identified at initial diagnosis. Such
patients can then be treated with more
aggressive regimens that may provide
improved outcomes.
Finally, the findings from this study
support the fact that primary tumor
populations demonstrate clear biological
heterogeneity. Moreover, both molecular
(gene expression) and functional (xeno-
graft transplantation) assays link current
definitions of stemness with clinical
behavior and prognosis for leukemia
patients. Going forward, it remains an
intriguing challenge to elucidate how
various aspects of stem cell biology are
related to clinical outcome. Two clues
come from previous studies that demon-
strate that normal and leukemia stem cells
naturally reside in a more quiescent cell
cycle state and also express relatively
high levels of proteins that function as
drug efflux pumps (ABCG2 and related
multidrug resistance proteins) (reviewed
in Jordan and Guzman, 2004). It is
possible that programs controlling basic
stem cell properties are intimately linked
to either cycle status or expression of
ABC family transporters, thereby explain-
ing why stemness is associated with
resistance to treatment with conventional11 Elsevier Inc.chemotherapy. If true, then the key objec-
tives in creating improved therapeutic
regimens should be to identify agents
that are (1) not dependent on cycle
status, (2) not substrates for efflux pump
proteins, and (3) have preferentially in-
creased activity in primitive leukemic cell
types. The data reported by Eppert et al.
provide exciting opportunities to design
new therapies that fulfill these criteria.REFERENCES
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